Abstract
ObjectivesIxekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A (IL-17A), has shown significant efficacy in the treatment of psoriatic arthritis (PsA) and sustained long-term clinical response without unexpected new...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have